Supplementary

Table S1 The CT/MRI scanning systems (vendors), and CECT/DCE-MRI protocols used for the enrolled patients

Parameter	CECT	DCE-MRI
Scanning systems (vendors)	Discovery CT750 HD, GE healthcare, USA; AquilionOne TSX-301A; TOSHIBA, Japan; Aquilion PRIME; TOSHIBA, Japan; BrightSpeed; GE Healthcare, USA; Optima CT660, GE Healthcare, USA; Brilliance iCT 256, Philips Healthcare, the Netherland)	MAGNETOM Skyra; Siemens Healthineers, Germany; Brivo MR 360;GE HealthCare; USA
Contrast agent	Iohexol, 350 mg/ml, Omnipaque™, GE HealthCare, USA; Iopromide, 370 mg/mL, Ultravist 370; Bayer Schering Pharma, Germany	MultiHance, Bracco Imaging, Italy
Injection rate	2.5 mL/s	2.5 mL/s
Dosage	1.5 mg/kg	0.1 mmol/kg

CECT: contrast-enhanced computed tomography; DCE-MRI: dynamic contrast-enhanced magnetic resonance imaging

Table S2 Detailed recurrence data for the present study group and the published group (2,4)

	Stage III gastric cancer in present study group (cases with FU, n=43)	Stage III gastric cancer in published group (4) (cases without FU, n=53)	Colorectal cancer in present study group (cases with FU, n=53)	Colorectal cancer in published group (2) (cases without FU, n=104)	P_1 value[a]	P_2 value[b]
Recurrence	10 (23.26%)	36 (67.92%)	13 (24.53%)	N/A	<0.001	N/A
In situ	4 (9.3%)	14 (26.42%)	0 (0)	20 (19.23%)	0.033	0.001
Peritoneal	3 (6.98%)	19 (35.85%)	4 (7.55%)	8 (7.69%)	0.001	1

a: P1 refers to the comparison between the study group and the published group (4) for stage III gastric cancers. b: P2 refers to the comparison between the study group and the published group (2) for colon cancers. Note: FU refers specifically to intraperitoneal fluorouracil implants in this study. N/A: not applicable.

Table S3 Intra-reader agreement of the diagnostic confidence and benign-malignant assessment in part two of the study

	Benign-malignant assessment	Diagnostic confidence
ICC	0.992	0.907
P value	<0.001	<0.001

ICC: intraclass correlation coefficient.

https://dx.doi.org/10.21037/qims-24-2033